Oral Versus Transdermal Ondansetron for Women With Cervical Cancer Receiving Chemoradiation
Information source: M.D. Anderson Cancer Center
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cancer of the Cervix
Intervention: Granisetron (Drug); Ondansetron (Drug); Questionnaires (Behavioral); Study Drug Diary (Behavioral)
Phase: Phase 3
Sponsored by: M.D. Anderson Cancer Center
Official(s) and/or principal investigator(s):
Michael M. Frumovitz, MD, MPH, Principal Investigator, Affiliation: UT MD Anderson Cancer Center
Michael M. Frumovitz, MD, MPH, Phone: 713-792-9599
The goal of this clinical research study is to compare granisetron (when given through a
patch) to ondansetron (when taken by mouth) for reducing nausea and vomiting in women with
cervical cancer having chemoradiation.
Granisetron and ondansetron are designed to help reduce nausea and vomiting.
Official title: Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical Cancer Receiving Chemoradiation
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Response to Anti-Emetic Therapy
If you agree to take part in this study, and you are among the first 40 participants, you
will have an equal chance of being in either group. If you enroll after that, you will have
a higher chance (51%-100%) of being assigned to the group that had better results.
- If you are in Group 1, you will receive granisetron by patch.
- If you are in Group 2, you will receive ondansetron by mouth.
Study Drug Administration:
If you are in Group 1, you will receive ondansetron by vein at your first visit only, which
is standard of care. Then, you will receive cisplatin by vein over about 1 hour as part of
the chemoradiation. A granisetron patch will then be placed on your skin before the
chemotherapy . The patch will be replaced every 7 days before the chemotherapy.
If you are in Group 2, you will receive ondansetron by vein before cisplatin. Then, you
will receive cisplatin by vein over about 1 hour. Then you will take ondansetron by mouth
with a cup of water (8 ounces) 3 times a day for 3 days. Ondansetron is a tablet that you
can take with or without food and is best taken at least 30 minutes before eating.
Both groups will be given a study drug diary to record the times that you take the study
drugs. You will also record any nausea or vomiting that you may have. You should bring the
diary to each study visit. You should also bring your study drug bottles/packages to each
The visits for this study will be at the same time as your chemoradiation therapy visits
over 5 weeks.
You will complete 3 questionnaires at your study visits and then again 1 week after the
last chemotherapy. The last questionnaires will be completed by phone. The questionnaires
ask about how easy or difficult it is to use your assigned study drug, your level of nausea
and vomiting, and your quality of life. It should take about 5 minutes to complete these
questionnaires each time.
Length of Treatment:
You may continue using the study drug up to 5 weeks during your chemoradiation treatment.
You will no longer be able to take the study drug if the disease gets worse, if intolerable
side effects occur, or if you are unable to follow study directions.
Your participation on the study will be over when you have completed 5 weeks of
This is an investigational study. Both granisetron and ondansetron are FDA approved and
commercially available for the treatment of nausea and vomiting. It is investigational to
compare these drugs administered in different ways.
Up to 150 patients will take part in this study. Up to 138 participants will take part at
MD Anderson. Up to 12 participants will take part at Lyndon B. Johnson General Hospital.
Minimum age: 18 Years.
Maximum age: N/A.
1. Women with biopsy-proven, locally advanced (stages IA2-IVA) cervical cancer
dispositioned to receive definitive pelvic radiation therapy with concurrent
2. Women receiving primary or adjuvant pelvic radiation with concurrent cisplatinum
postoperatively for cervical or endometrial cancer.
3. Women must be at least 18 years of age.
4. Women must be able to read English or Spanish at a sixth grade level.
5. Women with childbearing potential must have a negative pregnancy test within 1 week
of starting chemoradiation therapy
1. Women with cervical or endometrial cancer who are receiving chemotherapy and/or
radiation therapy for recurrent disease.
2. Women with cervical or endometrial cancer who are receiving extended field radiation
3. Women with cervical or endometrial cancer who are receiving chemotherapy and/or
radiation therapy in a palliative setting
Locations and Contacts
Michael M. Frumovitz, MD, MPH, Phone: 713-792-9599
UT MD Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
UT MD Anderson Cancer Center Website
Starting date: March 2012
Last updated: January 25, 2013